Skip to main content
. Author manuscript; available in PMC: 2021 Jun 1.
Published in final edited form as: Leukemia. 2020 May 27;34(12):3215–3227. doi: 10.1038/s41375-020-0872-3

Figure 2.

Figure 2.

Line graphs showing the impact of gene mutations found to be prognostically significant in multivariable models for a Non-core-binding factor acute myeloid leukemia (non-CBF-AML) patients in the 2017 European LeukemiaNet (ELN) Favorable-risk group, b CBF-AML Favorable-risk patients, c Intermediate-risk patients and d Adverse-risk patients on complete remission rates (left panel), 3-year disease-free survival rates (middle panel) and 3-year overall survival rates (right panel). The percentages are depicted for both wild-type (wt) and mutated (mut) patients, relative to the median rates according to the ELN genetic-risk classification (blue vertical bars). * mutated versus Intermediate-risk, P≤0.05 (adjusted for multiple comparisons); ** mutated versus Adverse-risk, P≤0.05 (adjusted for multiple comparisons).